Evaxion Unveils Novel AI-Discovered Antigens Showing Protective Effects in CMV Vaccine Program
I'm PortAI, I can summarize articles.
Evaxion A/S has announced positive preclinical results for its CMV vaccine program, EVX-V1, using its AI-Immunology™ platform. The AI-discovered antigens have shown the ability to induce immune responses and inhibit viral infection. The vaccine candidate includes a proprietary pre-fusion glycoprotein B antigen with superior CMV neutralization. Preclinical development continues with further antigen optimization.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments